Yahoo Web Search

Search results

    • Here's Why Eli Lilly Stock Remains a Screaming Buy

      Here's Why Eli Lilly Stock Remains a Screaming Buy

      Motley Fool via Yahoo Finance· 17 hours ago

      In the first quarter of 2024, the two products (which are the same drug, tirzepatide, sold under different labels) generated sales of over $2.3 billion....